Drug Discovery World

OCTOBER 18, 2023

4 Unfortunately, many AAV-based gene therapies fail during clinical trials, despite them appearing safe and efficacious in preclinical studies. Such therapies have become an appealing drug modality for multiple conditions, including monogenic disorders, cancers, and infectious diseases.

Gene Therapy 64

Gene Therapy Gene Clinical Trials Clinical Trials 64

BioSpace

NOVEMBER 17, 2022

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

Gene Therapy 42

Gene Therapy Gene Gene Editing Medicine 42

Drug Discovery World

JANUARY 19, 2023

In the first article, he talks to Lu Rahman about some of the company’s work developing medicine for eye disease and offers insight into the ophthalmology field today. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Drug Delivery 52

Drug Delivery Drugs Medicine Development 52

pharmaphorum

DECEMBER 18, 2020

Active Needle Technology, Xerion Healthcare and Medicines Discovery Catapult win funding to begin ground-breaking project. We’re delighted to be working with Medicines Discovery Catapult to take the technology one step closer to the clinic.”.

Drug Delivery 52

Drug Delivery Medicine Clinical Trials Clinical Trials 52

Roots Analysis

SEPTEMBER 1, 2023

By using real-world evidence , researchers can gain clinically useful insights that can help improve the quality of care delivery in precision medicine. As the field continues to advance, it is expected to have a profound impact on the future of medicine.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

pharmaphorum

OCTOBER 6, 2022

Most often, this has involved artificial recreation of natural molecules with medicinal properties; however, such a process is both time consuming and extremely costly. Indeed, it is through bio-orthogonal reactions that researchers have been able to improve the targeting of cancer pharmaceuticals now tested in clinical trials.

Drug Delivery 52

Drug Delivery DNA Medicine Research 52

pharmaphorum

NOVEMBER 25, 2022

With over 40% of all medicines in the pipeline aimed at rare diseases, and around 50 new therapies approved around the world each year, the future looks positive for increasing the number of treatments available. However, only 5% of rare diseases are estimated to have at least one approved treatment, known as “orphan” therapies.

Marketing 122

Marketing Clinical Trials Clinical Trials Production 122

Drug Discovery World

AUGUST 4, 2022

The growing hospital-to-home trend has motivated drugmakers to convert intravenous medicines into subcutaneous formulations that patients can self-administer. The development of easy to use, intuitive home administration devices, including wearable devices, that can deliver medicines to patients on demand is expanding. Never too early.

Containment 52

Containment Development Drugs Production 52

The Pharma Data

MARCH 15, 2022

For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections , Inc. to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience. Nicholas Galakatos, Ph.D.

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

Drug Discovery World

SEPTEMBER 13, 2023

Integrated drug formulation and clinical trials company, BDD Clinical Trials, has secured a further round of investment for £2M to aid the company’s expansion in response to growing demand for both its patented drug delivery technology and specialist clinical trial services.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drug Delivery 52

The Pharma Data

JANUARY 3, 2021

TLC19 Hydroxychloroquine Liposome Inhalation Suspension was thus incubated, with Phase I clinical trial currently taking place in Taiwan and Australia. Long before the emergence of COVID-19, TLC had already begun plans to apply its unique and proprietary technology platforms to lung diseases.

Clinical Trials 52

Clinical Trials Clinical Trials Containment Development 52

The Pharma Data

OCTOBER 20, 2020

“As a long-time watcher of TLC, I have observed improvements on all fronts and am impressed by the ripening pipeline and the efficiency of the development process of bringing life-changing medicines to patients.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

The Pharma Data

DECEMBER 20, 2020

“With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. About BetterLife Pharma Inc.

Drug Delivery 52

Drug Delivery Containment Production Development 52

The Pharma Data

NOVEMBER 26, 2020

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals with Opioid Use Disorder: A Randomized Clinical Trial.

Clinical Trials 52

Clinical Trials Clinical Trials Drug Delivery Production 52

The Pharma Data

JANUARY 3, 2021

4, 2021 /PRNewswire/ — Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a new near-term business target. Nanoform is an innovative nanoparticle medicine enabling company. HELSINKI , Jan. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

Roots Analysis

OCTOBER 13, 2023

Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drug delivery strategies to enhance the potent delivery of the drug to the site of action.

Drugs 40

Drugs Antibody RNA Genetics 40

The Pharma Data

JUNE 26, 2021

The safety profile of PDS in the clinical trial setting is well understood and will continue to be closely monitored. 9 Both the Pagoda and Pavilion trials are actively recruiting participants. The PDS Marketing Authorisation Application has also been validated by the European Medicines Agency and is currently under review.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

Drug Discovery World

FEBRUARY 5, 2024

Through early diagnosis and precision medicine, we can improve quality of life and enable more people with cancer to survive. Dr Gen Li, Founder and President, Phesi “In 2024, we can expect immunotherapy trials to become a driving force for change in clinical development.

Research 116

Research Drug Delivery Systems Gene Sequencing Trials 116

Drug Discovery World

JANUARY 12, 2023

Here, Thomas reflects specifically on Anita Cooper’s prediction relating to the importance of clinical trials. . Following the launch of Protas, DDW spoke with Protas Chief Executive, Professor Sir Martin Landray, who echoed Cooper’s emphasis on the importance of clinical trial design.

Clinical Trials 97

Clinical Trials Clinical Trials Drugs Trials 97

Delveinsight

JANUARY 22, 2021

This novel drug is designed to prevent complement-mediated inflammation and endothelial damage while maintaining the respective functions of the other pathways of innate immunity. The EC also granted narsoplimab designation as an orphan medicinal product for treatment in hematopoietic stem cell transplantation.

Marketing 65

Marketing Drugs Antibody Compliance 65

The Pharma Data

APRIL 12, 2023

2 6 About the Vabysmo ® ( faricimab ) clinical development programme Roche has a robust phase III clinical development programme for Vabysmo. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world.

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

JANUARY 15, 2021

Darzalex Faspro® is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials. patients in gaining access to Darzalex Faspro® through the Janssen CarePath Savings Program.

FDA Approval 52

FDA Approval Production Research Doctors 52

The Pharma Data

JANUARY 25, 2021

Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces a number of updates: 1. Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) isa drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines.

Containment 52

Containment Drug Delivery Licensing Licensing 52

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52